AR061652A1 - Derivados de pirimidina, un metodo para su preparacion, intermediarios para su sintesis, una composicion farmaceutica que los comprenden y el uso de los mismos en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de gsk3. - Google Patents

Derivados de pirimidina, un metodo para su preparacion, intermediarios para su sintesis, una composicion farmaceutica que los comprenden y el uso de los mismos en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de gsk3.

Info

Publication number
AR061652A1
AR061652A1 ARP070102831A ARP070102831A AR061652A1 AR 061652 A1 AR061652 A1 AR 061652A1 AR P070102831 A ARP070102831 A AR P070102831A AR P070102831 A ARP070102831 A AR P070102831A AR 061652 A1 AR061652 A1 AR 061652A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
halo
heterocyclyl
cyano
Prior art date
Application number
ARP070102831A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38846127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061652(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR061652A1 publication Critical patent/AR061652A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP070102831A 2006-06-27 2007-06-26 Derivados de pirimidina, un metodo para su preparacion, intermediarios para su sintesis, una composicion farmaceutica que los comprenden y el uso de los mismos en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de gsk3. AR061652A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81675606P 2006-06-27 2006-06-27

Publications (1)

Publication Number Publication Date
AR061652A1 true AR061652A1 (es) 2008-09-10

Family

ID=38846127

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102831A AR061652A1 (es) 2006-06-27 2007-06-26 Derivados de pirimidina, un metodo para su preparacion, intermediarios para su sintesis, una composicion farmaceutica que los comprenden y el uso de los mismos en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de gsk3.

Country Status (20)

Country Link
US (1) US20080188502A1 (enExample)
EP (1) EP2046782A4 (enExample)
JP (1) JP2009542638A (enExample)
KR (1) KR20090024817A (enExample)
CN (1) CN101511825A (enExample)
AR (1) AR061652A1 (enExample)
AU (1) AU2007265731A1 (enExample)
BR (1) BRPI0713576A2 (enExample)
CA (1) CA2655441A1 (enExample)
CL (1) CL2007001881A1 (enExample)
CO (1) CO6140059A2 (enExample)
EC (1) ECSP088973A (enExample)
IL (1) IL195666A0 (enExample)
MX (1) MX2008015720A (enExample)
NO (1) NO20090327L (enExample)
RU (1) RU2008148902A (enExample)
TW (1) TW200815418A (enExample)
UY (1) UY30440A1 (enExample)
WO (1) WO2008002244A2 (enExample)
ZA (1) ZA200810484B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006296386A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
AU2007265966B2 (en) * 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
EP2419425A4 (en) 2009-04-15 2012-08-29 Astrazeneca Ab IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS, SUCH AS ALZHEIMER'S DISEASE
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103724207B (zh) * 2013-12-20 2016-07-06 北京智博高科生物技术有限公司 苯基苄基醚类衍生物及其制备方法和应用
JP2017524739A (ja) 2014-07-17 2017-08-31 アンセルムＩｎｓｅｒｍ 神経筋接合部関連疾患の処置方法
UY36547A (es) 2015-02-05 2016-06-01 Bayer Cropscience Ag Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
AR105607A1 (es) 2015-08-07 2017-10-18 Bayer Cropscience Ag Derivados heterocíclicos condensados sustituidos por 2-(het)arilo como pesticidas
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7361665B2 (en) * 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
JP2007500178A (ja) * 2003-07-30 2007-01-11 サイクラセル・リミテッド プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体
BRPI0415759A (pt) * 2003-10-21 2006-12-19 Cyclacel Ltd compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US20090099160A1 (en) * 2004-12-17 2009-04-16 David Andrews 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
GB0504753D0 (en) * 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II

Also Published As

Publication number Publication date
CL2007001881A1 (es) 2008-02-08
JP2009542638A (ja) 2009-12-03
ECSP088973A (es) 2009-01-30
TW200815418A (en) 2008-04-01
WO2008002244A3 (en) 2008-02-14
CA2655441A1 (en) 2008-01-03
KR20090024817A (ko) 2009-03-09
RU2008148902A (ru) 2010-08-10
CN101511825A (zh) 2009-08-19
MX2008015720A (es) 2008-12-19
IL195666A0 (en) 2009-09-01
EP2046782A4 (en) 2010-10-13
WO2008002244A2 (en) 2008-01-03
UY30440A1 (es) 2008-01-31
EP2046782A2 (en) 2009-04-15
WO2008002244A8 (en) 2008-10-09
NO20090327L (no) 2009-02-09
AU2007265731A1 (en) 2008-01-03
BRPI0713576A2 (pt) 2012-10-23
CO6140059A2 (es) 2010-03-19
US20080188502A1 (en) 2008-08-07
ZA200810484B (en) 2009-08-26

Similar Documents

Publication Publication Date Title
AR046779A1 (es) Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer.
AR040408A1 (es) Derivados de benzotiadiazepina, procesos para su preparacion y composiciones farmaceuticas que los contienen
AR056556A1 (es) Imidazo(1,2-a)piridina con actividad antiproliferacion celular
AR063690A1 (es) Derivados de 1h-pirrol-2-il-carbonilo sustituidos, un metodo para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento util en el tratamiento de infecciones bacterianas.
AR064130A1 (es) Derivados de tiazoles y piridinas como antibacterianos. composiciones farmaceuticas.
AR078168A1 (es) Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119
CO6140059A2 (es) Derivados de imidazol-pirimidina para el tratamiento de enfermedades relacionadas con la glicogeno sintasa quinasa (gsk3)
AR049662A1 (es) Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer
AR054183A1 (es) Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas.
AR063643A1 (es) Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas
AR037736A1 (es) Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r)
AR053683A1 (es) Derivados de piperidina con actividad antibacteriana
MX2009000475A (es) Nuevos compuestos de espiropiperidina triciclicos, su sintesis y sus usos como moduladores de la actividad de los receptores de quimioquinas.
AR033836A1 (es) Compuesto 2-anilino-(imidazol-5-il)-pirimidina, composicion farmaceutica que lo comprende, su uso en la fabricacion de un medicamento que produce un efecto inhibitorio del ciclo celular y un proceso para su preparacion
TW200745111A (en) New compounds
AR056354A1 (es) DERIVADOS DE PIRAZOL, UN MÉTODO DE PREPARACIoN DEL COMPUESTO, COMPOSICIoN FARMACÉUTICA Y PREPARACIoN DE UN MEDICAMENTO
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
NZ579296A (en) Spirocyclic compounds as inhibitors of serine proteases for the treatment of HCV infections
AR053992A1 (es) Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
ES2920888T3 (es) Derivado de sulfonamida y método de preparación y uso del mismo
AR047890A1 (es) Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal